Maria-Victoria Mateos, MD, PhD, on Multiple Myeloma: Results From the ALCYONE Trial
2017 ASH Annual MeetingMaria-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, discusses phase III study findings on daratumumab plus bortezomib, melphalan, and prednisone vs bortezomib, melphalan, and prednisone in patients ineligible for transplant who have been newly diagnosed with multiple myeloma (Abstract LBA-4).
Related Videos
Michael Unterhalt, MD, on Mantle Cell Lymphoma: Long-Term Follow-up Results
Michael Unterhalt, MD, of the University Hospital Grosshadern, discusses study findings on rituximab maintenance after first-line immunochemotherapy among older patients who are no...
John F. Seymour, MBBS, PhD, on CLL: Results From the MURANO Study
John F. Seymour, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses an interim analysis of venetoclax plus rituximab vs bendamustine plus rituximab in patients with relapse...
Andrew D. Zelenetz, MD, PhD, and Sattva S. Neelapu, MD, on NHL: Results From the ZUMA-1 Trial
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center, discuss lo...
Joseph M. Connors, MD, on Untreated Hodgkin Lymphoma: Results From the ECHELON-1 Trial
Joseph M. Connors, MD, of the British Columbia Cancer Agency, discusses study findings on a new front-line option: brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazin...
Mark J. Roschewski, MD, on Burkitt Lymphoma: Clinical Trial Results on DA-EPOCH-R
Mark J. Roschewski, MD, of the National Cancer Institute, discusses phase II study findings that showed DA-EPOCH-R cures most adult patients with Burkitt lymphoma, irrespective of ...
